Journal
SCIENCE
Volume 311, Issue 5767, Pages 1621-1623Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1124875
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL76839] Funding Source: Medline
- NIAMS NIH HHS [AR050200] Funding Source: Medline
Ask authors/readers for more resources
Progerias are rare genetic diseases characterized by premature aging. Several progeroid disorders are caused by mutations that lead to the accumulation of a lipid-modified (farnesylated) form of prelamin A, a protein that contributes to the structural scaffolding for the cell nucleus. In progeria, the accumulation of farnesyl-prelamin A disrupts this scaffolding, leading to misshapen nuclei. Previous studies have shown that farnesyltransferase inhibitors (FTIs) reverse this cellular abnormality. We tested the efficacy of an FTI (ABT-100) in Zmpste24-deficient mice, a mouse model of progeria. The FTI-treated mice exhibited improved body weight, grip strength, bone integrity, and percent survival at 20 weeks of age. These results suggest that FTIs may have beneficial effects in humans with progeria.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available